Modifying T- and B-cells for gene therapy
Research type
Research Study
Full title
Modifying T- and B-cells for gene therapy
IRAS ID
291740
Contact name
Ryan Cawood
Contact email
Sponsor organisation
OXGENE
Clinicaltrials.gov Identifier
RD100187,
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Using surplus blood provided by the NHS blood and transport service, we will isolate T- and B-cells from peripheral blood and will study how well these are modified with exogenous DNA sequences for cell and gene therapy solutions.
Immunotherapy has emerged as one of the most promising therapeutic strategies in cancer. Delivery of exogenous DNA sequences can be implemented to produce therapeutic immune cells, such as construction of chimeric antigen receptor T (CAR-T) cells. In addition, B lymphocytes may also represent valuable immune cells that can be engineered for protein replacement therapy or recombinant antibody production. We aim to perform in both T- and B-cells: (1) AAV capsid screens to identify new viral capsids to improve specificity and efficacy for AAV-based immunotherapy treatments; (2) Promoter screens to discover synthetic promoters that drive gene expression with enhanced tissue specific activity; and (3) CRISPR-based functional screens to improve genetically reprogrammed cell-based therapies.REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
21/NW/0202
Date of REC Opinion
6 Jul 2021
REC opinion
Further Information Favourable Opinion